Norman David Eansor - Nov 12, 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Signature
/s/ Andrew Nick as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed.
Stock symbol
TECH
Transactions as of
Nov 12, 2021
Transactions value $
-$10,192,045
Form type
4
Date filed
11/16/2021, 03:51 PM
Previous filing
Sep 2, 2021
Next filing
May 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Options Exercise $3.4M +27.2K +2060.62% $125.05 28.5K Nov 12, 2021 Direct
transaction TECH Common Stock Sale -$353K -700 -2.46% $504.09 27.8K Nov 12, 2021 Direct F1
transaction TECH Common Stock Sale -$101K -200 -0.72% $504.78 27.6K Nov 12, 2021 Direct
transaction TECH Common Stock Sale -$151K -300 -1.09% $502.99 27.3K Nov 12, 2021 Direct F2
transaction TECH Common Stock Sale -$271K -537 -1.97% $504.14 26.7K Nov 12, 2021 Direct F3
transaction TECH Common Stock Sale -$202K -400 -1.5% $505.01 26.3K Nov 12, 2021 Direct F4
transaction TECH Common Stock Sale -$2.04M -4.05K -15.39% $502.77 22.3K Nov 12, 2021 Direct F5
transaction TECH Common Stock Sale -$4.55M -9.04K -40.58% $503.61 13.2K Nov 12, 2021 Direct F6
transaction TECH Common Stock Sale -$4.53M -8.99K -67.88% $504.39 4.25K Nov 12, 2021 Direct F7
transaction TECH Common Stock Sale -$1.28M -2.54K -59.59% $505.49 1.72K Nov 12, 2021 Direct F8
transaction TECH Common Stock Sale -$203K -401 -23.33% $506.24 1.32K Nov 12, 2021 Direct F9
transaction TECH Common Stock Options Exercise $99.9K +799 +60.62% $125.05 2.12K Nov 16, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -27.2K -97.14% $0.00 799 Nov 12, 2021 Common Stock 27.2K $125.05 Direct F11
transaction TECH Stock Options (Right to Buy) Options Exercise $0 -799 -100% $0.00* 0 Nov 16, 2021 Common Stock 799 $125.05 Direct F11
holding TECH Stock Options (Right to Buy) 13.6K Nov 12, 2021 Common Stock 13.6K $177.32 Direct F11
holding TECH Stock Options (Right to Buy) 18.1K Nov 12, 2021 Common Stock 18.1K $177.32 Direct F12
holding TECH Restricted Stock Units 3.15K Nov 12, 2021 Common Stock 3.15K Direct F10, F13
holding TECH Stock Options (Right to Buy) 15.9K Nov 12, 2021 Common Stock 15.9K $190.41 Direct F13
holding TECH Stock Options (Right to Buy) 21.3K Nov 12, 2021 Common Stock 21.3K $190.41 Direct F14
holding TECH Restricted Stock Units 2.58K Nov 12, 2021 Common Stock 2.58K Direct F10, F15
holding TECH Stock Options (Right to Buy) 11.5K Nov 12, 2021 Common Stock 11.5K $267.87 Direct F15
holding TECH Stock Options (Right to Buy) 15.3K Nov 12, 2021 Common Stock 15.3K $267.87 Direct F16
holding TECH Stock Options (Right to Buy) 25K Nov 12, 2021 Common Stock 25K $267.87 Direct F17
holding TECH Stock Options (Right to Buy) 25K Nov 12, 2021 Common Stock 25K $267.87 Direct F18
holding TECH Restricted Stock Units 1.56K Nov 12, 2021 Common Stock 1.56K Direct F10, F19
holding TECH Stock Options (Right to Buy) 6.08K Nov 12, 2021 Common Stock 6.08K $481.82 Direct F19
holding TECH Stock Options (Right to Buy) 8.11K Nov 12, 2021 Common Stock 8.11K $481.82 Direct F20
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.78 to $504.535, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.62 to $503.33, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.77 to $504.745, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.97 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.11 to $503.10, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $503.11 to $504.107, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.13 to $505.11, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.13 to $506.07, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.20 to $506.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F10 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F11 Fully exercisable.
F12 Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
F13 Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14 Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.
F15 Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16 Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024.
F17 Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F18 Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
F19 Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F20 Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025.